U.S. Markets closed
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • Dow 30

    33,978.08
    +28.67 (+0.08%)
     
  • Nasdaq

    11,621.71
    +109.30 (+0.95%)
     
  • Russell 2000

    1,911.46
    +8.39 (+0.44%)
     
  • Crude Oil

    79.38
    -1.63 (-2.01%)
     
  • Gold

    1,943.90
    -2.80 (-0.14%)
     
  • Silver

    23.73
    -0.30 (-1.23%)
     
  • EUR/USD

    1.0874
    -0.0018 (-0.1631%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • Vix

    18.51
    -0.22 (-1.17%)
     
  • GBP/USD

    1.2395
    -0.0012 (-0.0967%)
     
  • USD/JPY

    129.8000
    -0.3530 (-0.2712%)
     
  • BTC-USD

    22,980.29
    +35.87 (+0.16%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,382.56
    +19.81 (+0.07%)
     

Company News for Oct 27, 2022

  • Shares of Moderna, Inc. MRNA rose 4% after reports emerged that it was close to winning a deal with the U.S. government to develop vaccines against ebola and other biological threats.

  • Visa Inc.’s V shares gained 4.6% after the company reported fourth-quarter fiscal 2022 earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.86 per share.

  • Shares of Canadian National Railway Company CNI rose 3.4% after the company reported third-quarter 2022 earnings of $1.63 per share, beating the Zacks Consensus Estimate of $1.51 per share.

  • The Boeing Company’s BA shares plunged 8.8% after reporting third-quarter 2022 revenues of $15.96 billion, widely missing the Zacks Consensus Estimate of $17.50 billion.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
The Boeing Company (BA) : Free Stock Analysis Report
 
Visa Inc. (V) : Free Stock Analysis Report
 
Canadian National Railway Company (CNI) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research